5F-AB-PINACA has been reported to be a potent
agonist of the
CB1 receptor and
CB2 receptor with
EC50 values of 0.48 nM and 2.6 nM respectively.[3] Its metabolism has been described in literature.[4][5]
Legality
China
As of October 2015 5F-AB-PINACA is a controlled substance in China.[6]
Germany
5F-AB-PINACA is an
Anlage II controlled substance in Germany as of May 2015.[7]
Singapore
It is also controlled under the Fifth Schedule of the Misuse of Drugs Act (MDA) in Singapore as of May 2015.[8]
^WO 2009106980, Buchler I, Hayes M, Hegde S, Hockerman S, Jones D, Kortum S, Rico J, Tenbrink R, Wu KK, "Indazole derivatives", published 2009-09-03, assigned to Pfizer
^Banister SD, Moir M, Stuart J, Kevin RC, Wood KE, Longworth M, et al. (September 2015). "Pharmacology of Indole and Indazole Synthetic Cannabinoid Designer Drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA". ACS Chemical Neuroscience. 6 (9): 1546–59.
doi:
10.1021/acschemneuro.5b00112.
PMID26134475.
^Jang M, Shin I, Kim J, Yang W (July 2015). "Simultaneous quantification of 37 synthetic cannabinoid metabolites in human urine by liquid chromatography-tandem mass spectrometry". Forensic Toxicology. 33 (2): 221–234.
doi:
10.1007/s11419-015-0265-x.
S2CID3038555.
^"关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from
the original on 1 October 2015. Retrieved 1 October 2015.